Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What does the time for peak plasma concentration (Tmax) indicate?

The rate of absorption. ***The rate of absorption*** - **Tmax** is the time at which the **maximum drug concentration** in the plasma is reached [1]. - A shorter **Tmax** indicates a faster rate at which the drug is absorbed from its administration site into the systemic circulation [1]. *The rate of elimination* - The rate of elimination is primarily reflected by the **elimination half-life (t½)** of the drug, which is the time it takes for the plasma concentration to decrease by half. - While Tmax is influenced by both absorption and elimination, it does not directly indicate the elimination rate [1]. *The duration of effect* - The **duration of effect** is related to how long the drug concentration remains above the minimum effective concentration (MEC), which is influenced by both absorption and elimination, but not directly indicated by Tmax alone. - A drug's duration of action is better described by its **elimination half-life** and the **therapeutic window**. *The intensity of effect* - The **intensity of effect** is largely related to the **maximum plasma concentration (Cmax)** and the drug's affinity for its target, and not directly by the time it takes to reach that concentration. - **Cmax** indicates how much drug is in the bloodstream, which often correlates with the intensity of the pharmacological response.

Q: What does ED50 measure in pharmacology?

Potency. ***Potency*** - **ED50** (Effective Dose 50%) is the dose of a drug that produces a **therapeutic effect** in 50% of the population or the maximum effect in 50% of subjects [3, 4]. - It is a key measure of a drug's **potency**: a lower ED50 indicates higher potency [1, 3]. *Toxicity* - **Toxicity** is primarily measured by **LD50** (Lethal Dose 50%), which indicates the dose at which 50% of the population would die [3, 4]. - While related to drug safety, ED50 does not directly quantify toxicity. *Safety* - **Safety** is evaluated using the **therapeutic index**, which ideally compares the **TD50** (Toxic Dose 50%) or **LD50** to the ED50 [3, 4]. - ED50 alone measures effectiveness, not the margin between effective and toxic doses. *Efficacy* - **Efficacy** refers to the **maximal response** a drug can produce, regardless of the dose [1]. - A drug with high efficacy might have a high or low ED50, as efficacy is about the *height* of the effect, not the *dose* at which it occurs [1].

Q: Which of the following statements about drug distribution in tissues is NOT true?

Ephedrine - bone. ***Ephedrine - bone*** - This statement is **NOT true**. **Ephedrine** is a sympathomimetic amine that does not have clinically significant accumulation in **bone tissue**. - While ephedrine distributes to various tissues due to its physicochemical properties, there is **no established evidence** of preferential or significant bone accumulation that is clinically relevant. - Unlike the other drug-tissue pairs listed, this pairing lacks strong pharmacokinetic evidence. *Chloroquine - eye* - This statement is **true**. **Chloroquine** (and hydroxychloroquine) accumulates significantly in the **retina** and **cornea**, leading to **retinal toxicity** (e.g., bull's eye maculopathy) with chronic use. - Ocular side effects are a significant concern with long-term chloroquine therapy, necessitating regular **ophthalmological monitoring**. *Minocycline - adipose tissue* - This statement is **true**. **Minocycline** is a highly **lipophilic tetracycline** that accumulates significantly in **adipose tissue**. - Its high lipid solubility allows extensive tissue distribution, including fat stores, contributing to its **prolonged elimination half-life** (15-23 hours). - This lipophilicity also enables excellent CNS penetration and wide tissue distribution. *Digoxin - skeletal muscle* - This statement is **true**. **Digoxin** has a large volume of distribution (5-7 L/kg) primarily due to its significant binding to **skeletal muscle** and **cardiac muscle**, where it exerts its therapeutic effects. - Its accumulation in skeletal muscle contributes to its prolonged **elimination half-life** and wide distribution pattern.

Q: Which of the following causes an increase in cAMP levels?

Beta (β) receptor. ***Beta (β) receptor*** - **Beta-adrenergic receptors** (β1, β2, β3) are G-protein coupled receptors that, when activated, couple to **Gs proteins**, leading to the activation of **adenylyl cyclase**. - **Adenylyl cyclase** then catalyzes the conversion of **ATP to cAMP**, thereby increasing intracellular cAMP levels and triggering downstream signaling pathways. *Alpha (α) receptor* - **Alpha-1 adrenergic receptors** (α1) typically couple to **Gq proteins**, leading to the activation of **phospholipase C**, which increases **intracellular calcium** and activates protein kinase C, not cAMP. - **Alpha-2 adrenergic receptors** (α2) couple to **Gi proteins**, which inhibit adenylyl cyclase, thereby **decreasing cAMP levels**. *Somatostatin* - **Somatostatin receptors** are G-protein coupled receptors that primarily couple to **Gi proteins**. - Activation of **Gi proteins** leads to the **inhibition of adenylyl cyclase**, resulting in a **decrease in cAMP levels**. *Acetylcholine* - **Acetylcholine** acts on **muscarinic** and **nicotinic receptors**. Muscarinic receptors (M2 and M4) couple to **Gi proteins**, which **decrease cAMP production**. - Other muscarinic receptors (M1, M3, M5) couple to **Gq proteins**, leading to increased **intracellular calcium**, not cAMP.

Q: The therapeutic index of a drug is defined as the ratio between the toxic dose and the effective dose.

Ratio of toxic dose to effective dose. ***Ratio of toxic dose to effective dose***- The **therapeutic index (TI)** is quantitatively defined as the ratio of the toxic dose (TD50 or LD50) to the effective dose (ED50) [1, 2].- This ratio provides a measure of **drug safety**, indicating the range between the therapeutic and toxic concentrations [1, 3].*Margin of safety*- While related to safety, the **margin of safety** is a different concept, often calculated as (TD1 - ED99) / ED99, focusing on the overlap between very few people experiencing toxicity and almost everyone receiving benefit [2].- The therapeutic index is a broader, simpler ratio that doesn't explicitly guarantee overlap safety but indicates overall drug risk.*Efficacy of the drug*- **Efficacy** refers to the maximal effect a drug can produce regardless of the dose, and it is independent of the therapeutic index [2].- A drug can have high efficacy but a narrow therapeutic index, meaning it is very effective but also very toxic at doses slightly above the therapeutic range.*Drug potency*- **Potency** is the amount of drug needed to produce a given effect (e.g., ED50), reflecting its affinity for receptors and efficiency of action [2].- It is distinct from the therapeutic index, which assesses the separation between desired and undesired effects, not the concentration required to achieve a therapeutic effect.

Q: Major mechanism of transport of drugs across biological membranes is:

Passive diffusion. ***Passive diffusion*** - This is the **most common mechanism** for drug transport across biological membranes, especially for **lipid-soluble** drugs. - It occurs down a **concentration gradient** and does not require energy or carrier proteins. *Facilitated diffusion* - This process requires **carrier proteins** to move drugs across membranes, but it still occurs down a **concentration gradient** and does not consume energy directly. - It handles substances that are **too large or too polar** to cross by passive diffusion, but it is not the primary mechanism for most drugs. *Active transport* - This mechanism uses **carrier proteins** and **expends energy (ATP)** to move drugs against their **concentration gradient**. - It is important for the transport of specific drugs, but it is not the predominant mode for the majority of drug molecules. *Endocytosis* - This involves the **engulfment of large molecules** or particles by the cell membrane, forming vesicles. - It is a less common mechanism for drug absorption, primarily used for **very large molecules** like proteins or nanoparticles.

Q: Phase 1 biotransformation includes

Reduction. ***Reduction*** - **Phase 1 biotransformation reactions** are non-synthetic reactions that introduce or expose polar functional groups (e.g., -OH, -NH2, -SH) on xenobiotics to make them more water-soluble. - The three main Phase 1 reactions are **oxidation**, **reduction**, and **hydrolysis**. - These reactions typically involve **cytochrome P450 enzymes** and prepare drugs for excretion or Phase 2 conjugation. *Acetylation* - **Acetylation** is a **Phase 2 (conjugation) reaction**, not Phase 1. - Involves transfer of an acetyl group to amine-containing drugs via **N-acetyltransferase**. - Increases water solubility and facilitates excretion. *Sulfate conjugation* - **Sulfate conjugation** is a **Phase 2 (conjugation) reaction**, not Phase 1. - Involves addition of a sulfate group via **sulfotransferase enzymes**. - Significantly increases hydrophilicity for renal excretion. *Methylation* - **Methylation** is a **Phase 2 (conjugation) reaction**, not Phase 1. - Involves addition of a methyl group via **methyltransferase enzymes**. - Unlike most Phase 2 reactions, methylation may sometimes **decrease** water solubility but is still classified as conjugation.

Q: In the context of drug metabolism, which enzyme system is primarily responsible for the Phase I metabolism of xenobiotics?

Cytochrome P-450. **Cytochrome P-450** - The **Cytochrome P-450 (CYP450) enzyme system** is a superfamily of enzymes primarily located in the liver that are crucial for Phase I **biotransformation** of xenobiotics. - Phase I reactions, which include **oxidation**, reduction, and hydrolysis, typically introduce or expose a polar functional group on the drug molecule, making it more hydrophilic and often less active. *Glutathione S-transferase* - **Glutathione S-transferases (GSTs)** are involved in **Phase II metabolism**, which involves conjugation reactions to highly polar molecules like glutathione, making compounds more water-soluble for excretion. - They play a key role in the **detoxification** of electrophilic compounds and products of oxidative stress, but not Phase I oxidation. *NADPH cytochrome P-450-reductase* - **NADPH cytochrome P-450 reductase** is an essential enzyme that **supplies electrons** to the cytochrome P-450 enzymes. - While critical for the function of CYP450, it is a **cofactor** or electron donor, not the primary enzyme system responsible for the metabolic reaction itself. *Glucuronyl transferase* - **Glucuronyl transferases (UGTs)** are involved in **Phase II metabolism**, specifically **glucuronidation**, which conjugates a drug or metabolite with glucuronic acid. - This process significantly increases the **water solubility** of the compound, facilitating its elimination from the body.

Q: The neurotransmitters noradrenaline, adrenaline, and dopamine act through which of the following receptors?

Seven-pass transmembrane receptor. ***Seven-pass transmembrane receptor*** - Noradrenaline, adrenaline, and dopamine are **catecholamines** that primarily activate **G-protein coupled receptors (GPCRs)**, which are characterized by having seven transmembrane domains. - These receptors mediate a wide range of physiological responses by initiating **intracellular signaling cascades** upon ligand binding. *Single-pass transmembrane receptor* - These receptors, such as **receptor tyrosine kinases**, cross the membrane only once and typically dimerize upon ligand binding to activate their intracellular kinase domains. - While important for growth factors and hormones, they are **not the primary receptors** for catecholamines. *Four-pass transmembrane receptor* - This type of receptor structure is less common for neurotransmitters and is not characteristic of the established receptors for **noradrenaline, adrenaline, and dopamine**. - Examples include some **gap junction proteins** and a subset of ion channels, but not the **adrenergic** or **dopaminergic receptors**. *Ligand-gated ion channel* - These channels directly open in response to ligand binding, allowing ions to pass and rapidly changing the **membrane potential**. - While some neurotransmitters like **acetylcholine (nicotinic receptors)** and **GABA** act this way, catecholamines primarily exert their effects through **GPCRs**, which modulate ion channel activity indirectly.

Question 1

What does the time for peak plasma concentration (Tmax) indicate?

Accepted Answer

The rate of absorption

Answer

The rate of elimination

Answer

The duration of effect

Answer

The intensity of effect

Question 2

What does ED50 measure in pharmacology?

Accepted Answer

Potency

Answer

Toxicity

Answer

Safety

Answer

Efficacy

Question 3

Which of the following statements about drug distribution in tissues is NOT true?

Accepted Answer

Ephedrine - bone

Answer

Minocycline - adipose tissue

Answer

Digoxin - skeletal muscle

Answer

Chloroquine - eye

Question 4

Which of the following causes an increase in cAMP levels?

Accepted Answer

Beta (β) receptor

Answer

Alpha (α) receptor

Answer

Somatostatin

Answer

Acetylcholine

Question 5

The therapeutic index of a drug is defined as the ratio between the toxic dose and the effective dose.

Accepted Answer

Ratio of toxic dose to effective dose

Answer

Margin of safety

Answer

Efficacy of the drug

Answer

Drug potency

Question 6

Major mechanism of transport of drugs across biological membranes is:

Accepted Answer

Passive diffusion

Answer

Facilitated diffusion

Answer

Active transport

Answer

Endocytosis

Question 7

Phase 1 biotransformation includes

Accepted Answer

Reduction

Answer

Methylation

Answer

Acetylation

Answer

Sulfate conjugation

Question 8

In the context of drug metabolism, which enzyme system is primarily responsible for the Phase I metabolism of xenobiotics?

Accepted Answer

Cytochrome P-450

Answer

Glutathione S-transferase

Answer

NADPH cytochrome P-450-reductase

Answer

Glucuronyl transferase

Question 9

In isolated intestinal smooth muscle preparations, drug X binds to cholinergic receptors and causes relaxation. In the absence of drug X, acetylcholine binds to the same receptors and causes contraction. At low concentrations of drug X, the efficacy (Emax) of acetylcholine is decreased, but its potency (EC50) remains unchanged. At high concentrations of drug X, acetylcholine has no effect. Which of the following statements about drug X is true?

Accepted Answer

Non-competitive antagonist

Answer

A chemical antagonist

Answer

A physiologic antagonist

Answer

Competitive antagonist

Question 10

The neurotransmitters noradrenaline, adrenaline, and dopamine act through which of the following receptors?

Accepted Answer

Seven-pass transmembrane receptor

Answer

Single-pass transmembrane receptor

Answer

Four-pass transmembrane receptor

Answer

Ligand-gated ion channel

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?